Invenomic Capital Management

• July 2026 Commentary ↗ The Invenomic Fund benefited from a sharp momentum-factor reversal while maintaining relatively steady net exposure and reducing gross exposure as short positions generated outsized gains. It argues that AI-linked valuations remain optimistic, citing hyperscalers' off-balance-sheet commitments, rising debt burdens and uncertainty over the durability of the AI buildout. July 2026 —

One letter so far. We collect each new one as Invenomic Capital Management publishes it.